

New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma

Tweetorial #2 References: First-line Therapy

Tweet 5

Suzman DL, Agrawal S, Ning Y, et al. FDA approval summary: atezolizumab or pembrolizumab for the treatment of patients with advanced urothelial carcinoma ineligible for cisplatin-containing chemotherapy. *The Oncologist*. 2018;24:4. <https://doi.org/10.1634/theoncologist.2018-0084>

Tweet 6

Balar AV, Dreicer R, Loriot Y, et al. Atezolizumab (atezo) in first-line cisplatin-ineligible or platinum-treated locally advanced or metastatic urothelial cancer (mUC): Long-term efficacy from phase 2 study IMvigor210. *J Clin Oncol*. 2018;36:15. https://doi.org/10.1200/JCO.2018.36.15_suppl.4523

Tweet 7

O'Donnell PH, Balar AV, Vuky J, et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study. *J Clin Oncol*. 2021;39:4508. https://doi.org/10.1200/JCO.2021.39.15_suppl.4508

Tweet 9

Galsky MD, Ariba JAA, Bamias A, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. *The Lancet*. 2020;395:10236. [https://doi.org/10.1016/S0140-6736\(20\)30230-0](https://doi.org/10.1016/S0140-6736(20)30230-0)

Tweet 10

Tewari A. ESMO Virtual Congress 2020: Pembrolizumab Combined with Chemotherapy vs Chemotherapy Alone as First-Line Therapy for Advanced Urothelial Carcinoma: KEYNOTE-361. Presented at the European Society for Medical Oncology Virtual Congress, ESMO Virtual Congress 2020; September 18-21 2020; Virtual.

Tweet 11

Powles T, van der Heijden M, Castellano D, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. *The Lancet Oncology*. 2020;21:12. [https://doi.org/10.1016/S1470-2045\(20\)30541-6](https://doi.org/10.1016/S1470-2045(20)30541-6)

Tweet 13

Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. *N Engl J Med*. 2020; 383:1218-1230. <https://doi.org/10.1056/NEJMoa2002788>

Klaassen Z. ASCO GU 2021: Avelumab first-line maintenance plus best supportive care vs best supportive care alone for advanced urothelial carcinoma: JAVELIN bladder 100 subgroup analysis based on duration and cycles of first-line chemotherapy. Presented at: 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (#GU21), February 11th- 13th, 2021. Virtual.

Glossary

AE, adverse event
Atezo, atezolizumab
aUC, advanced urothelial carcinoma, including metastatic and locally advanced/unresectable disease
Avel, avelumab
1L, first-line
bf, before
BICR, blinded independent central review
BSC, best supportive care
Carbo, carboplatin
Cis, cisplatin
CR, complete response
CPS, cycles per second
ctcae, common terminology criteria for adverse events
Durva, durvalumab
ECOG, Eastern Cooperative Oncology Group
IC, immune cell
Gem, gemcitabine
ICIs, immune checkpoint inhibitors
ITT, intention to treat
IV, intravenous
m, months
mL/min, milliliters per minute
mDOR, median duration of response
mOS, median overall survival
mUC, metastatic UC oncology
ODAC, Oncology Drugs Advisory Committee
ORR, overall response rate
OS, overall survival
PD-L1, programmed death-ligand
Pembro, pembrolizumab
PFS, progression-free survival
Ph, phase
PR, partial response
Pt, platinum
pts, patients
q3w, every 3 weeks
RCT, randomized controlled trial
RR, risk ratio
SOC, CIS-based chemo
TRAEs, treatment-related adverse events
Tx, treatment
UC, urothelial carcinoma
Y, year
YO, year old